Open Access
Volume 8, Number 3, September 2018
Article Number 18
Number of page(s) 8
Published online 24 August 2018
  1. Momenimovahed Z, Ghoncheh M, Pakzad R, Hasanpour H, Salehiniya H. Incidence and mortality of uterine cancer and relationship with Human Development Index in the world. Cukurova Med J. 2017; 42(2): 233–40. [CrossRef] [Google Scholar]
  2. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017 Aug 15; 141(4): 664–70. [CrossRef] [PubMed] [Google Scholar]
  3. Cecilia NC, Rosliza A, Suriani I. Global Burden of Cervical Cancer: A Literature Review. International Journal of Public Health and Clinical Sciences. 2017; 4(2). [Google Scholar]
  4. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Globocan 2012 v1. 0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International agency for research on cancer. 2013;19. [Google Scholar]
  5. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 2004; 4(1): 46–55. [CrossRef] [PubMed] [Google Scholar]
  6. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Elsevier; 2015. [Google Scholar]
  7. Denny L. Cervical cancer: prevention and treatment. Discov Med. 2012; 14(75): 125–31. [PubMed] [Google Scholar]
  8. Topp J, Gordon J. Pap Smears and Cervical Cancer. Aboriginal and Islander Health Worker Journal. 1987; 11(2): 30. [Google Scholar]
  9. Momenimovahed Z, Salehiniya H. Incidence, mortality and risk factors of cervical cancer in the world. Biomedical Research and Therapy. 2017; 4(12): 1795–811. [CrossRef] [Google Scholar]
  10. Giuliano AR, Nyitray AG, Kreimer AR, Pierce Campbell CM, Goodman MT, Sudenga SL, et al. EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015; 136(12): 2752–60. [CrossRef] [PubMed] [Google Scholar]
  11. Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. The Lancet. 2002; 359(9312): 1093–101. [CrossRef] [Google Scholar]
  12. Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control. 2003; 14(9): 805–14. [CrossRef] [PubMed] [Google Scholar]
  13. García-Closas R, Castellsagué X, Bosch X, González CA. The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence. Int J Cancer. 2005; 117(4): 629–37. [CrossRef] [PubMed] [Google Scholar]
  14. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ. 2001; 164(7): 1017–25. [PubMed] [Google Scholar]
  15. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. The Lancet. 2013; 382(9895): 889–99. [CrossRef] [Google Scholar]
  16. Katz SJ, Hofer TP. Socioeconomic disparities in preventive care persist despite universal coverage: breast and cervical cancer screening in Ontario and the United States. Jama. 1994; 272(7): 530–4. [CrossRef] [PubMed] [Google Scholar]
  17. Downs LS, Smith JS, Scarinci I, Flowers L, Parham G. The disparity of cervical cancer in diverse populations. Gynecol Oncol. 2008; 109(2): S22–S30. [CrossRef] [PubMed] [Google Scholar]
  18. Goel MS, Wee CC, McCarthy EP, Davis RB, Ngo-Metzger Q, Phillips RS. Racial and ethnic disparities in cancer screening. J Gen Intern Med. 2003; 18(12): 1028–35. [CrossRef] [Google Scholar]
  19. Ferley J, SoerjomataramI I, Ervik M, Dikshit R, Eser S. Globocan 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] . Lyon, Fr Int Agency Res Cancer. 2013. [Google Scholar]
  20. Allahverdipour H, Emami A. Perceptions of cervical cancer threat, benefits, and barriers of Papanicolaou smear screening programs for women in Iran. Women Health. 2008; 47(3): 23–37. [CrossRef] [Google Scholar]
  21. Farjadian S, Asadi E, Doroudchi M, Dehaghani AS, Tabei S, Kumar V, et al. High risk HPV types in southern Iranian patients with cervical cancer. Pathol Oncol Res. 2003; 9(2): 121–5. [CrossRef] [Google Scholar]
  22. Ghaffari SR, Sabokbar T, Mollahajian H, Dastan J, Ramezanzadeh F, Ensani F, et al. Prevalence of human papillomavirus genotypes in women with normal and abnormal cervical cytology in Iran. Asian Pac J Cancer Prev. 2006; 7(4): 529–32. [PubMed] [Google Scholar]
  23. Khorasanizadeh F, Hassanloo J, Khaksar N, Taheri SM, Marzaban M, Rashidi BH, et al. Epidemiology of cervical cancer and Human Papillomavirus infection among Iranian women-Analyses of national data and systematic review of the literature. Gynecologic oncology. 2013; 128(2): 277–81. [CrossRef] [Google Scholar]
  24. Arab M, Noghabaei G, Kazemi SN. Comparison of crude and age-specific incidence rates of breast, ovary, endometrium and cervix cancers in Iran, 2005. Asian Pac J Cancer Prev. 2014; 15(6): 2461–4. [CrossRef] [Google Scholar]
  25. Maliheh A, Noghabaei G. Comparison of Age-Standard Incidence Rate Trends of Gynecologic and Breast Cancer in Iran and Other Countries. Iran J Public Health. 2014; 43(10): 1372. [PubMed] [Google Scholar]
  26. Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R, et al. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol. 2007; 37(1): 147–60. [CrossRef] [Google Scholar]
  27. Benard VB, Thomas CC, King J, Massetti GM, Doria-Rose VP, Saraiya M, et al. Vital signs: cervical cancer incidence, mortality, and screening-United States, 2007-2012. MMWR Morb Mortal Wkly Rep. 2014; 63(44): 1004–9. [PubMed] [Google Scholar]
  28. Sreedevi A, Javed R, Dinesh A. Epidemiology of cervical cancer with special focus on India. Int J Womens Health. 2015; 7: 405. [PubMed] [Google Scholar]
  29. Obel J, Souares Y, Hoy D, Baravilala W, Garland S, Kjaer S, et al. A systematic review of cervical cancer incidence and mortality in the Pacific region. Asian Pac J Cancer Prev. 2014; 15(21): 9433–7. [CrossRef] [Google Scholar]
  30. Talaiezadeh A, Tabesh H, Sattari A, Ebrahimi S. Cancer incidence in southwest of iran: first report from khuzestan population-based cancer registry, 2002-2009. Asian Pac J Cancer Prev. 2013; 14(12): 7517–22. [CrossRef] [Google Scholar]
  31. Fateh M, Emamian MH. Cancer incidence and trend analysis in Shahroud, Iran, 2000-2010. Iran J Cancer Prev. 2013; 6(2): 85. [PubMed] [Google Scholar]
  32. Taheri N, Fazel A, Mahmoodzadeh H, Omranpour R, Roshandel G, Gharahjeh S, et al. Epidemiology of female reproductive cancers in Iran: results of the Gholestan Population-based Cancer Registry. Asian Pac J Cancer Prev. 2014; 15(20): 8779–82. [CrossRef] [Google Scholar]
  33. Mohagheghi S, Mousavi Js, Malekzadeh R, Parkin M. Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry. 1998-2001. 2009. [Google Scholar]
  34. Babaei M, Jafarzadeh H, Sajadi S, Samadi F, Yazdanbod A, Falah M, et al. Cancer incidence and mortality in Ardabil: Report of an ongoing population-based cancer registry in Iran. 2004-2006. 2009. [Google Scholar]
  35. Chaichian S, Khateri S, Moradi Y, Shadmani FK, Mansori K, Khazaei Z, et al. Trends in Cervical Cancer Incidence in Iran from 2003 to 2009. Middle East J Cancer. 2017; 9(1): 57–63. [Google Scholar]
  36. Vaisy A, Lotfinejad S, Zhian F. Risk Factors for Cervical Cancer among Women Referred to Health Services Centers of Tehran University of Medical Sciences. J Ardabil Univ Med Sci. 2013; 13(3): 327–36. [Google Scholar]
  37. Nojomi M, Gilani M, Erfani A, Mozafari N, Mottaghi A. The study of frequency of risk factors of cervical cancer among women attending general hospitals in Tehran, 2005-2006. RJMS. 2007; 14(56): 189–95. [Google Scholar]
  38. Karimi MZ, Akhavan A, Gholami H, Dehghani A, Naghshi M, Mohseni F. Evaluation of cervical cancer risk-factors in women referred to Yazd-Iran hospitals from 2002 to 2009. Asian Pacific journal of cancer prevention: APJCP. 2010; 11(2): 537–8. [Google Scholar]
  39. Taherian Aa, Fatahi E. Study of Effective Factors in Cervical Cancer in Isfahan. 2001. [Google Scholar]
  40. Vaisy A, Lotfinejad S, Zhian F. Risk of cancer with combined oral contraceptive use among Iranian women. Asian Pac J Cancer Prev. 2014; 15(14): 5517–22. [CrossRef] [Google Scholar]
  41. Vaisy A. Sexual Behaviors Among Iranian Women With Cervical Cancer. Sexual Addiction & Compulsivity. 2014; 21(4): 263–75. [CrossRef] [Google Scholar]
  42. Boheyraei A, Jafari N, Azima S, Mahmoudi M. Association Between the Common Methods of Contraceptive Use and Invasive Cervical Carcinoma. 2006. [Google Scholar]
  43. Mohaghegh F, Ahmadlou M. A Study of the Prevalence of Cervical Cancer among Married Wemon in Arak, 2013. J Arak Uni Med Sci. 2015; 18(4): 65–70. [Google Scholar]
  44. Dehaghani AS, Amirzargar A, Farjadian S, Ghaderi A. HLA-DQB1 alleles and susceptibility to cervical squamous cell carcinoma in Southern Iranian patients. Pathol Oncol Res. 2002; 8(1): 58–61. [CrossRef] [PubMed] [Google Scholar]
  45. Jafari M, Halimi M, Dastranj Tabrizi A, Shahamfar J. Prevalence of for precancerous and invasive cancer lesions of Cervix Tabriz 20032005. IJOGI. 2007; 10(2): 63–78. [Google Scholar]
  46. Arbyn M, Walker A, Meijer CJ. HPV-based cervical-cancer screening in China. Lancet Oncol. 2010; 11(12): 1112–3. [CrossRef] [PubMed] [Google Scholar]
  47. Jalilvand S, Shoja Z, Nourijelyani K, Tohidi HR, Hamkar R. Metaanalysis of type-specific human papillomavirus prevalence in Iranian women with normal cytology, precancerous cervical lesions and invasive cervical cancer: Implications for screening and vaccination. J Med Virol. 2015; 87(2): 287–95. [CrossRef] [PubMed] [Google Scholar]
  48. Allameh T, Moghim S, Asadi-Zeidabadi M. A survey on the prevalence of high-risk subtypes of Human Papillomavirus among women with cervical neoplasia in Isfahan University of Medical Science. Arch Gynecol Obstet. 2011; 284(6): 1509–13. [CrossRef] [PubMed] [Google Scholar]
  49. Sadeghi A, Sobhani A, Etaati Z, Jahanlou A, Shiroudi M. Prevalence of Human Papillomavirus among women with cervical intraepithelial neoplasia III and invasive cervical cancer from 2001 to 2006 in Bandarabas. 2008. [Google Scholar]
  50. Khodakarami N, Clifford GM, Yavari P, Farzaneh F, Salehpour S, Broutet N, et al. Human papillomavirus infection in women with and without cervical cancer in Tehran, Iran. Int J Cancer. 2012; 131(2). [CrossRef] [PubMed] [Google Scholar]
  51. Mortazavi S, Zali M, Raoufi M, Nadji M, Kowsarian P, Nowroozi A. The prevalence of human papillomavirus in cervical cancer in Iran. Asian Pac J Cancer Prev. 2002; 3(1): 69–72. [PubMed] [Google Scholar]
  52. Safaei A, Khanlari M, Momtahen M, Monabati A, Robati M, Amooei S, et al. Prevalence of high-risk human papillomavirus types 16 and 18 in healthy women with cytologically negative pap smear in Iran. Indian J Pathol Microbiol. 2010; 53(4): 681. [CrossRef] [PubMed] [Google Scholar]
  53. Khodakarami N, Farzaneh F, Yavari P, Khayamzadeh M, Taheripanah R, Esmaeil Akbari M. The New Guideline for Cervical Cancer Screening in Low Risk Iranian Women. The Iranian Journal of Obstetrics, Gynecology and Infertility. 2014;17(95):8–17. [Google Scholar]
  54. Khodakarami N, Farzaneh F, Yavari P, Akbari ME. Cervical Cancer Screening: Recommendations for Muslim Societies. APJCP. 2016; 17(1): 239–47. [Google Scholar]
  55. Nahvijou A, Daroudi R, Tahmasebi M, Hashemi FA, Hemami MR, Sari AA, et al. Cost-effectiveness of different cervical screening strategies in Islamic Republic of Iran: a middle-income country with a low incidence rate of cervical cancer. PloS one. 2016; 11(6): e0156705. [CrossRef] [PubMed] [Google Scholar]
  56. Nokiani FA, Akbari H, Rezaei M, Madani H, Ale Agha M. Cost-effectiveness of pap smear in Kermanshah, Iran. Asian Pac J Cancer Prev. 2008; 9(1): 107–10. [PubMed] [Google Scholar]
  57. Javanmanesh F, Dadkhah F, Zarepour N. Knowledge and awareness among Iranian women regarding the pap smear. MJIRI. 2008; 22(2): 68–73. [Google Scholar]
  58. Jalalvandi M, Khodadoostan M. Married women and pap smear, what they know? how they do? IJN. 2005; 18(41): 139–44. [Google Scholar]
  59. Farzaneh F, Shirvani HE, Barouti E, Salehpour S, Khodakarami N, Alizadeh K. Knowledge and attitude of women regarding the human papillomavirus (HPV) infection, its relationship to cervical cancer and prevention methods. Med J Malaysia. 2011; 66(5): 468–73. [PubMed] [Google Scholar]
  60. Asgarlou Z, Tehrani S, Asghari E, Arzanlou M, Naghavi-Behzad M, Piri R, et al. Cervical Cancer Prevention Knowledge and Attitudes among Female University Students and Hospital Staff in Iran. APJCP. 2016; 17(11): 4921. [Google Scholar]
  61. Mojahed S, Zarchi MK, Bokaie M, Salimi T. Attitude and knowledge of Iranian female nurses about Human Papilomavirus infection and cervical cancer: a cross-sectional survey. J Prev Med Hyg. 2013; 54(3): 187. [PubMed] [Google Scholar]
  62. Rezaie CS, Mohammad ACS, Kamalifard M. Knowledge, attitudes and practice about pap smear among women reffering to a public hospital. 2012. [Google Scholar]
  63. Shakibazaeh E, Ahmadnia E, Akbari F, Negarandeh R. Barriers and Motivating Factors Related to Cervical Cancer Screening. Hayat. 2008; 14. [Google Scholar]
  64. Akbari F, Shakibazadeh E, Pourreza A, Tavafian S. Barriers and facilitating factors for cervical cancer screening: A qualitative study from Iran. Iran J Cancer Prev. 2010; 3(4): 178–84. [Google Scholar]
  65. Keshavarz Z, Simbar M, Ramezankhani A. Factors for performing breast and cervix cancer screening by Iranian female workers: a qualitative-model study. Asian Pac J Cancer Prev. 2011; 12(6): 1517–22. [PubMed] [Google Scholar]
  66. Saberi F, Sadat Z, Abedzadeh M. Factors associated with cervical cancer screening and its barriers among women: Kashan, Iran. 2012. [Google Scholar]
  67. Jalilian F, Emdadi S. Factors related to regular undergoing Pap-smear test: application of theory of planned behavior. J Res Health Sci. 2011; 11(2): 103–8. [PubMed] [Google Scholar]
  68. Bayrami R, Taghipour A, Ebrahimipour H. Challenges of providing cervical cancer prevention programs in Iran: a qualitative study. Asian Pac J Cancer Prev. 2014; 15: 10071–7. [CrossRef] [PubMed] [Google Scholar]
  69. Bahmani A, Baghianimoghadam MH, Enjezab B, Mahmoodabad SSM, Askarshahi M. Factors affecting cervical cancer screening behaviors based on the precaution adoption process model: a qualitative study. Glob J Health Sci. 2016; 8(6): 211. [CrossRef] [Google Scholar]
  70. Shojaeizadeh D, Hashemi SZ, Moeini B, Poorolajal J. The effect of educational program on increasing cervical cancer screening behavior among women in Hamadan, Iran: Applying health belief model. J Res Health Sci. 2011; 11(1): 20–5. [PubMed] [Google Scholar]
  71. Afrakhteh M, Khodakarami N, Moradi A, Alavi E, Shirazi FH. A study of 13315 papanicolau smear diagnoses in Shohada Hospital. J Family Reprod Health. 2007; 1(2): 74–8. [Google Scholar]
  72. Zarchi MK, Akhavan A, Fallahzadeh H, Gholami H, Dehghani A, Teimoori S. Outcome of cervical cancer in Iranian patients according to tumor histology, stage of disease and therapy. Asian Pac J Cancer Prev. 2010; 11: 1289–91. [PubMed] [Google Scholar]
  73. Majidi A, Ghiasvand R, Hadji M, Nahvijou A, Mousavi A-S, Pakgohar M, et al. Priority setting for improvement of cervical cancer prevention in Iran. Int J Health Policy Manag. 2016; 5(4): 225. [CrossRef] [Google Scholar]
  74. Khatibi M, Rasekh HR, Shahverdi Z. Cost-effectiveness evaluation of quadrivalent Human Papillomavirus vaccine for HPV-related disease in Iran. Iran J Pharm Res. 2014; 13(Suppl): 225. [PubMed] [Google Scholar]